NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)CARDIOVASCULAR RESEARCH FOUNDATION, founded in 1991, is a mid-sized nonprofit in the Medical Research sector that reported $78.3M in total revenue in fiscal year 2023. Revenue surged 28% from the prior year, signaling strong growth momentum. The organization ran a surplus of $13.3M, a strong 17% operating margin.
TO HELP DOCTORS IMPROVE THE SURVIVAL AND QUALITY OF LIFE FOR PEOPLE SUFFERING FROM HEART AND VASCULAR DISEASE THROUGH INNOVATION, INVESTIGATION AND EDUCATION.
CLINICAL TRIALS CENTER - A DISTINGUISHED ACADEMIC RESEARCH ORGANIZATION, THE CRF CLINICAL TRIALS CENTER (CTC) PLANS AND EXECUTES CLINICAL INVESTIGATIONS FROM FIRST-IN-MAN STUDIES TO LARGE...
CLINICAL TRIALS CENTER - A DISTINGUISHED ACADEMIC RESEARCH ORGANIZATION, THE CRF CLINICAL TRIALS CENTER (CTC) PLANS AND EXECUTES CLINICAL INVESTIGATIONS FROM FIRST-IN-MAN STUDIES TO LARGE, MULTICENTER INTERNATIONAL TRIALS DESIGNED TO GAIN INSIGHTS THAT WILL ELEVATE THE QUALITY OF CARE IN CARDIOVASCULAR MEDICINE. THE CTC SPECIALIZES IN TRIAL DESIGN, EVENT ADJUDICATION, DATA AND SAFETY MONITORING, AND BIO STATISTICAL SERVICES. CRF FACULTY AUTHOR OVER 300 ARTICLES ANNUALLY IN PRESTIGIOUS MEDICAL AND SCIENTIFIC JOURNALS, BRINGING THE LATEST RESEARCH TO THE GLOBAL MEDICAL COMMUNITY.
SKIRBALL CENTER FOR INNOVATION - A STATE OF THE ART INNOVATION CENTER, THE CRF SKIRBALL CENTER FOR INNOVATION IS DEDICATED TO THE INVESTIGATION AND VALIDATION OF NOVEL CONCEPTS, TREATMENTS, AND...
SKIRBALL CENTER FOR INNOVATION - A STATE OF THE ART INNOVATION CENTER, THE CRF SKIRBALL CENTER FOR INNOVATION IS DEDICATED TO THE INVESTIGATION AND VALIDATION OF NOVEL CONCEPTS, TREATMENTS, AND DEVICES. OUR PREEMINENT TEAM OF PIONEERING RESEARCHERS AND THOUGHT LEADERS CONTINUALLY BREAK NEW GROUND AS THEY GUIDE EARLY IDEAS AND INVENTIONS THROUGH COMPREHENSIVE PRECLINICAL RESEARCH PROGRAMS TO INTRODUCE PRACTICAL THERAPIES INTO CLINICAL MEDICINE.
TCT 2023 (TRANSCATHETER CARDIOVASCULAR THERAPEUTICS) MEETING - THE CARDIOVASCULAR RESEARCH FOUNDATION (CRF) STANDS AT THE FOREFRONT OF EDUCATION IN CARDIOVASCULAR MEDICINE. THIS FOCUS REFLECTS THE...
TCT 2023 (TRANSCATHETER CARDIOVASCULAR THERAPEUTICS) MEETING - THE CARDIOVASCULAR RESEARCH FOUNDATION (CRF) STANDS AT THE FOREFRONT OF EDUCATION IN CARDIOVASCULAR MEDICINE. THIS FOCUS REFLECTS THE CRF FACULTY'S COMMITMENT TO SHARING AND DISSEMINATING THE LATEST CLINICAL RESEARCH INFORMATION TO THE BROADEST AUDIENCE AT THE EARLIEST POSSIBLE DATE. THE FUNDAMENTAL GOAL OF CRF'S EDUCATION PROGRAM IS TO ENABLE THE GLOBAL PHYSICIAN COMMUNITY TO APPLY IMPORTANT NEW KNOWLEDGE TO ACTUAL PATIENT CARE. CRF'S PRINCIPAL ANNUAL EDUCATIONAL EVENT, TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT) MEETING, IS THE WORLD'S LARGEST EDUCATIONAL MEETING DEDICATED TO THE FIELD OF INTERVENTIONAL VASCULAR THERAPY. THIS IS THE SHOWCASE EDUCATIONAL EVENT IN THE CARDIOVASCULAR FIELD AND IS USED TO EDUCATE AND EXCHANGE STUDY FINDINGS AND TO IMPROVE TREATMENT OF PATIENTS WHO HAVE CARDIOVASCULAR DISEASE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $78,271,229 | $61,324,834 | +0.3% |
| Expenses | $64,971,760 | $57,291,678 | +0.1% |
| Net Income | $13,299,469 | $4,033,156 | +2.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JUAN F GRANADA MD | CEO & DIRECTOR | 37.50 |
Officer
Director
|
$945,463 | $72,139 | $1,017,602 |
| ERIC B WOLDENBERG | CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JOSEPH G BECK | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| COLETTE Y GARDNER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| WILLIAM A HIMMELSBACH | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JEFFREY W MOSES MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| TERESA LESTE | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| ERIC A ROSE MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MARVIN L WOODALL | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| KAREN G KRASNEY | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| FRANK LITVACK MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DONALD L ABRAMS | CHIEF LEGAL OFFICER | 37.50 |
Officer
|
$471,379 | $25,997 | $497,376 |
| EILEEN MORALES | CFO | 37.50 |
Officer
|
$450,290 | $38,225 | $488,515 |
| DAVID COHEN | DIRECTOR OF CLINICAL & OUT | 37.50 |
Highest
|
$704,590 | $30,000 | $734,590 |
| ALEXANDRA POPMA | DIRECTOR | 37.50 |
Highest
|
$437,422 | $0 | $437,422 |
| TRICIA RAWH | EXECUTIVE DIRECTOR, CED | 37.50 |
Highest
|
$406,000 | $22,512 | $428,512 |
| GRZEGORZ KALUZA | DIRECTOR RESEARCH | 37.50 |
Highest
|
$314,867 | $66,848 | $381,715 |
| DANIEL BURKOFF | DIRECTOR OF HEART FAILURE | 37.50 |
Highest
|
$316,055 | $56,556 | $372,611 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $78,271,229 | $64,971,760 | $91,969,884 | $13,299,469 |
| 2022 | $61,324,834 | $57,291,678 | $76,093,334 | $4,033,156 |
| 2021 | $52,277,749 | $47,332,137 | $57,426,030 | $4,945,612 |
| 2020 | $37,490,664 | $41,452,402 | $55,991,119 | $-3,961,738 |
| 2019 | $65,620,319 | $55,971,546 | $60,748,866 | $9,648,773 |
| 2018 | $60,750,509 | $54,012,608 | $47,712,737 | $6,737,901 |
Compare CARDIOVASCULAR RESEARCH FOUNDATION with other nonprofits in New York and across the country.